CN114727946A - 药物递送制剂 - Google Patents

药物递送制剂 Download PDF

Info

Publication number
CN114727946A
CN114727946A CN202080077874.0A CN202080077874A CN114727946A CN 114727946 A CN114727946 A CN 114727946A CN 202080077874 A CN202080077874 A CN 202080077874A CN 114727946 A CN114727946 A CN 114727946A
Authority
CN
China
Prior art keywords
risperidone
formulation
days
biodegradable
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080077874.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·雷什
C·罗贝热
E·哈拉里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matheson Ag
Original Assignee
Matheson Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matheson Ag filed Critical Matheson Ag
Publication of CN114727946A publication Critical patent/CN114727946A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CN202080077874.0A 2019-09-13 2020-09-11 药物递送制剂 Pending CN114727946A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
US62/900,061 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Publications (1)

Publication Number Publication Date
CN114727946A true CN114727946A (zh) 2022-07-08

Family

ID=72521677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080077874.0A Pending CN114727946A (zh) 2019-09-13 2020-09-11 药物递送制剂

Country Status (19)

Country Link
US (3) US12383493B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706658A3 (cg-RX-API-DMAC7.html)
JP (2) JP7661312B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062372A (cg-RX-API-DMAC7.html)
CN (1) CN114727946A (cg-RX-API-DMAC7.html)
AU (2) AU2020346455B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004535A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153793A1 (cg-RX-API-DMAC7.html)
DK (1) DK4027973T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058225T3 (cg-RX-API-DMAC7.html)
FI (1) FI4027973T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251690T1 (cg-RX-API-DMAC7.html)
IL (1) IL291283A (cg-RX-API-DMAC7.html)
LT (1) LT4027973T (cg-RX-API-DMAC7.html)
MX (1) MX2022003051A (cg-RX-API-DMAC7.html)
PL (1) PL4027973T3 (cg-RX-API-DMAC7.html)
PT (1) PT4027973T (cg-RX-API-DMAC7.html)
SI (1) SI4027973T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048817A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120569188A (zh) * 2023-01-10 2025-08-29 美蒂森股份公司 奥氮平组合物和使用方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007343A1 (en) * 1997-08-08 1999-02-18 University Of Utah Research Foundation Injectable biodegradable block copolymer gels for use in drug delivery
CN101584652A (zh) * 2009-06-19 2009-11-25 上海医药(集团)有限公司 利培酮缓释凝胶注射剂及其制备方法
CN103491946A (zh) * 2010-12-29 2014-01-01 美蒂森 可生物降解的药物释放组合物
CN104582733A (zh) * 2012-06-27 2015-04-29 美蒂森 用于疏水性组合物的可生物降解的药物释放系统
CN105163719A (zh) * 2013-03-11 2015-12-16 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
CN111107840A (zh) * 2017-07-17 2020-05-05 美蒂森 药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4223961B2 (ja) 2002-01-31 2009-02-12 Agcテクノグラス株式会社 霊長類胚性幹細胞の凍結保存方法
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
KR101707791B1 (ko) 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007343A1 (en) * 1997-08-08 1999-02-18 University Of Utah Research Foundation Injectable biodegradable block copolymer gels for use in drug delivery
CN101584652A (zh) * 2009-06-19 2009-11-25 上海医药(集团)有限公司 利培酮缓释凝胶注射剂及其制备方法
CN103491946A (zh) * 2010-12-29 2014-01-01 美蒂森 可生物降解的药物释放组合物
CN104582733A (zh) * 2012-06-27 2015-04-29 美蒂森 用于疏水性组合物的可生物降解的药物释放系统
CN105163719A (zh) * 2013-03-11 2015-12-16 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
CN111107840A (zh) * 2017-07-17 2020-05-05 美蒂森 药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120569188A (zh) * 2023-01-10 2025-08-29 美蒂森股份公司 奥氮平组合物和使用方法

Also Published As

Publication number Publication date
CA3153793A1 (en) 2021-03-18
AU2020346455A1 (en) 2022-03-31
JP2022548616A (ja) 2022-11-21
US20220331240A1 (en) 2022-10-20
JP7661312B2 (ja) 2025-04-14
BR112022004535A2 (pt) 2022-06-07
MX2022003051A (es) 2022-06-14
HRP20251690T1 (hr) 2026-02-13
US12128132B2 (en) 2024-10-29
IL291283A (en) 2022-05-01
ES3058225T3 (en) 2026-03-09
US12383493B2 (en) 2025-08-12
EP4706658A2 (en) 2026-03-11
US20250268817A1 (en) 2025-08-28
DK4027973T3 (da) 2026-01-12
PT4027973T (pt) 2026-01-05
AU2020346455B2 (en) 2025-07-03
FI4027973T3 (fi) 2026-01-14
PL4027973T3 (pl) 2026-03-09
SI4027973T1 (sl) 2026-02-27
LT4027973T (lt) 2026-01-26
WO2021048817A1 (en) 2021-03-18
EP4706658A3 (en) 2026-06-03
EP4027973B1 (en) 2025-11-05
US20240156722A1 (en) 2024-05-16
EP4027973A1 (en) 2022-07-20
JP2025106353A (ja) 2025-07-15
AU2025242078A1 (en) 2025-10-23
EP4027973B8 (en) 2025-12-17
KR20220062372A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
US12128132B2 (en) Drug delivery formulations
JP6134788B2 (ja) 疎水性組成物のための生分解性薬物送達
AU2011350898B2 (en) Biodegradable drug delivery compositions
US11801217B2 (en) Biodegradable block copolymer drug delivery composition
BR122025009310A2 (pt) Formulações de entrega de fármaco
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
HK1208374B (en) Biodegradable drug delivery for hydrophobic compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination